HighVista Strategies has divested 69,092 shares of Structure Therapeutics, translating to an estimated $4.73 million based on average pricing for the first quarter, according to a recent SEC filing. This sale reduced HighVista’s stake in the company to 1.6491% of its reportable U.S. equity AUM, reflecting a quarter-end value drop of $7.45 million due to both the sale and market fluctuations.

This move comes as Structure Therapeutics has seen its stock surge approximately 60% over the past year, significantly outperforming the S&P 500’s 25% gain. The company is at the forefront of developing innovative oral therapeutics for chronic diseases, particularly in the obesity and diabetes sectors, with promising clinical updates and a robust cash position of around $1.5 billion to fund operations through 2028.

For market professionals, this transaction highlights the ongoing volatility and rebalancing strategies among investors in high-growth biotech stocks, especially those in the competitive GLP-1 therapy space. Structure’s strong clinical data and financial backing position it as a noteworthy player amid rising investor expectations.

Source: fool.com